- Home
- BLIN vs TOVX Comparison
BLIN vs TOVX Comparison
Compare BLIN & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLIN | TOVX |
|---|---|---|
| Founded | 2000 | 2001 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 14.7M |
| IPO Year | 2018 | 2012 |
Fundamental Metrics
Financial Performance| Metric | BLIN | TOVX |
|---|---|---|
| Price | $1.18 | $0.23 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $4.62 | $1.00 |
| AVG Volume (30 Days) | 146.4K | ★ 1.5M |
| Earning Date | 05-14-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $13,568,000.00 | N/A |
| Revenue This Year | $22.67 | N/A |
| Revenue Next Year | $21.08 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.69 | $0.16 |
| 52 Week High | $1.74 | $0.86 |
Technical Indicators
Market Signals| Indicator | BLIN | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 53.57 | 41.29 |
| Support Level | $0.86 | $0.22 |
| Resistance Level | $1.30 | $0.27 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 35.16 | 14.94 |
Price Performance
Historical ComparisonAbout BLIN Bridgeline Digital Inc.
Bridgeline Digital Inc is a AI-powered marketing technology company that offers a suite of products that help companies grow online revenue by driving more traffic to their websites, converting more visitors to purchasers, and increasing average order value. Company software is available through a cloud-based Software as a Service (SaaS) model. It helps to maximize the performance of critical websites, intranets, and online stores. The company generates revenue from digital engagement services, subscription, perpetual licenses, maintenance, and hosting. Geographically, it derives a majority of revenue from the United States.
About TOVX Theriva Biologics Inc.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.